GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (FRA:LOBE) » Definitions » Short Percentage of Float

Lobe Sciences (FRA:LOBE) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Lobe Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Lobe Sciences's Short Percentage of Float

For the Biotechnology subindustry, Lobe Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Short Percentage of Float falls into.


Lobe Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (FRA:LOBE) » Definitions » Short Percentage of Float
Comparable Companies
TSXV:QPT TSXV:XRTX XCNQ:MYND TSXV:IBO TSX:APLI XCNQ:ASEP XCNQ:AWKN XCNQ:MBIO XCNQ:GTTX TSXV:MRVL VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
LOBEF:USA LOBE:Canada
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Website
https://www.lobesciences.com
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.

Lobe Sciences Headlines

No Headlines